Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies mo...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 July 2016
|
| In: |
Journal der Deutschen Dermatologischen Gesellschaft
Year: 2016, Jahrgang: 14, Heft: 7, Pages: 662-681 |
| ISSN: | 1610-0387 |
| DOI: | 10.1111/ddg.13047 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/ddg.13047 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.13047 
|
| Verfasserangaben: | Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer; for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1586276727 | ||
| 003 | DE-627 | ||
| 005 | 20220815090955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190116s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ddg.13047 |2 doi | |
| 035 | |a (DE-627)1586276727 | ||
| 035 | |a (DE-576)516276727 | ||
| 035 | |a (DE-599)BSZ516276727 | ||
| 035 | |a (OCoLC)1341033297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kähler, Katharina C. |d 1977- |e VerfasserIn |0 (DE-588)129795674 |0 (DE-627)48040142X |0 (DE-576)29783942X |4 aut | |
| 245 | 1 | 0 | |a Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma |c Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer; for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) |
| 264 | 1 | |c 4 July 2016 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.01.2019 | ||
| 520 | |a CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015.Immune responses thus induced and enhanced inevitably entail autoimmune phenomena, affecting various organs to varying degrees. Knowledge of these side effects is crucial with regard to prevention and management by treating physicians. Typically occurring early on and presenting with pronounced and persistent diarrhea, colitis represents a major and severe side effect. Other immune-mediated disorders include dermatitis, hypophysitis, thyroiditis, hepatitis, iridocyclitis as well as other less common autoimmune phenomena. Early recognition and initiation of treatment can reduce risks and sequelae for patients.This review describes the mechanisms of action of immune checkpoint blockade as well as its clinical effects in metastatic melanoma, with a detailed focus on the spectrum of adverse events and their therapeutic management. | ||
| 650 | 4 | |a autoimmune side effects | |
| 650 | 4 | |a CTLA-4 antibody | |
| 650 | 4 | |a immune checkpoint blockade | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a PD-1 antibody | |
| 650 | 4 | |a side effect management | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a Deutsche Dermatologische Gesellschaft |t Journal der Deutschen Dermatologischen Gesellschaft |d Berlin : Wiley-Blackwell, 2003 |g 14(2016), 7, Seite 662-681 |h Online-Ressource |w (DE-627)362755833 |w (DE-600)2099463-1 |w (DE-576)103373837 |x 1610-0387 |7 nnas |
| 773 | 1 | 8 | |g volume:14 |g year:2016 |g number:7 |g pages:662-681 |g extent:19 |a Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ddg.13047 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.13047 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190116 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 2 | ||
| 999 | |a KXP-PPN1586276727 |e 3045801269 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer; for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO)"]},"id":{"doi":["10.1111/ddg.13047"],"eki":["1586276727"]},"physDesc":[{"extent":"19 S."}],"recId":"1586276727","person":[{"display":"Kähler, Katharina C.","family":"Kähler","given":"Katharina C.","role":"aut"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."}],"relHost":[{"part":{"volume":"14","year":"2016","extent":"19","text":"14(2016), 7, Seite 662-681","issue":"7","pages":"662-681"},"id":{"eki":["362755833"],"issn":["1610-0387"],"zdb":["2099463-1"],"doi":["10.1111/(ISSN)1610-0387"]},"pubHistory":["1.2003 -"],"titleAlt":[{"title":"JDDG"}],"corporate":[{"display":"Deutsche Dermatologische Gesellschaft","role":"aut"}],"title":[{"subtitle":"JDDG = Journal of the German Society of Dermatology","title_sort":"Journal der Deutschen Dermatologischen Gesellschaft","title":"Journal der Deutschen Dermatologischen Gesellschaft"}],"note":["Gesehen am 03.03.10"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger","eng"],"origin":[{"dateIssuedKey":"2003","dateIssuedDisp":"2003-","publisherPlace":"Berlin ; Berlin","publisher":"Wiley-Blackwell ; Blackwell"}],"disp":"Deutsche Dermatologische GesellschaftJournal der Deutschen Dermatologischen Gesellschaft","titleTranslated":[{"translated":"Journal of the German Society of Dermatology"}],"recId":"362755833","physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"4 July 2016"}],"note":["Gesehen am 16.01.2019"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma","title":"Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma"}]} | ||
| SRT | |a KAEHLERKATMANAGEMENT4201 | ||